Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

Lipids in Health and Disease

Research

Jeffrey B. Rosen¹  Jose G. Jimenez²  Rachid Massaad³  Philippe Brudi⁴  Joseph Triscari⁴  Mary E. Hanson⁴  Valdis Pirags⁵  Hella Vides⁶ 

[1] Clinical Research of South Florida, Coral Gables, FL, USA;Hospital CIMA San Jose, Escazu, San Jose, Costa Rica;MSD Belgium, Brussels, Belgium;Merck & Co, Inc., Whitehouse Station, NJ, USA;University of Latvia, Riga, Latvia;Viljandi Hospital, Vildjandimaa, Estonia;

关键词: Atorvastatin;    Ezetimibe;    Diabetes;    Obesity;    Rosuvastatin;    Statin;   

DOI  :  10.1186/1476-511X-12-103

 received in 2013-04-23, accepted in 2013-07-08,  发布年份 2013

来源: Springer

【 摘 要 】

PurposeThis post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese (BMI ≥30 kg/m2) and non-obese (BMI <30 kg/m2) diabetic subjects.MethodsThis was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids was estimated.ResultsIn obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin. In non-obese subjects (n = 342), percent changes in LDL-C, total cholesterol, non-HDL-C, Apo B and Apo A-I were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin; and treatment with ezetimibe/simvastatin resulted in greater changes in triglycerides vs rosuvastatin and HDL-C vs doubling the baseline statin dose. The safety profiles were generally similar.ConclusionsRegardless of baseline obesity status, switching to ezetimibe/simvastatin was more effective at reducing LDL-C, total cholesterol, non-HDL-C, and Apo B vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg.

【 授权许可】

CC BY   
© Rosen et al.; licensee BioMed Central Ltd. 2013